Matrix-Bio Options Metabolite Biomarker Technology from Purdue University to Evaluate Opportunities for New Cancer Diagnostic Tests
Posted June 5, 2013 by Matrix-Bio • No Comments
FORT WAYNE, IND., June 5, 2013 – Matrix-Bio Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive agreement with the Purdue Research Foundation optioning metabolite biomarker technology and eight patent applications to evaluate the commercial potential of cancer diagnostics tests based on the technologies.
No comments yet.
Sorry, the comment form is closed at this time.